BCDA Insider Trading (BioCardia)
Insider Ownership Percentage: 23.30%
Insider Buying (Last 12 Months): $55,305.24
Insider Selling (Last 12 Months): $0.00
BioCardia Share Price & Price History
Current Price: $1.47
Price Change: ▲ Price Increase of +0.03 (2.08%)
As of 06/30/2022 11:24 AM ET
27 U.S. Cities Where Stocks Yield 26% a Year
From Investing Daily | Ad
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!
When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.
BioCardia Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/10/2022 | Peter Altman | CEO | Buy | 4,500 | $1.46 | $6,570.00 | 321,197 |  |
| 5/13/2022 | Peter Altman | CEO | Buy | 2,698 | $1.38 | $3,723.24 | 348,143 | |
| 5/11/2022 | Peter Altman | CEO | Buy | 1,000 | $1.30 | $1,300.00 | 334,143 | |
| 4/28/2022 | Peter Altman | CEO | Buy | 2,300 | $1.59 | $3,657.00 | 330,443 | |
| 4/18/2022 | Peter Altman | CEO | Buy | 13,500 | $1.39 | $18,765.00 | 328,143 | |
| 11/18/2021 | Peter Altman | CEO | Buy | 5,000 | $2.20 | $11,000.00 | | |
| 8/17/2021 | Peter Altman | CEO | Buy | 3,500 | $2.94 | $10,290.00 | 232,909 | |
| 12/1/2020 | Peter Altman | CEO | Buy | 1,000 | $2.49 | $2,490.00 | 203,200 | |
| 11/27/2020 | Peter Altman | CEO | Buy | 3,200 | $2.37 | $7,584.00 | 203,200 | |
| 11/12/2020 | Peter Altman | CEO | Buy | 2,000 | $2.07 | $4,140.00 | 205,900 | |
| 11/10/2020 | Peter Altman | CEO | Buy | 2,500 | $1.98 | $4,950.00 | 203,900 | |
| 11/2/2020 | Eric Duckers | Insider | Sell | 8,435 | $2.01 | $16,954.35 | 12,088 | |
| 6/19/2020 | Jim L Allen | Director | Buy | 142,850 | $2.10 | $299,985.00 | 668,200 | |
| 3/24/2020 | Peter Altman | CEO | Buy | 1,200 | $2.90 | $3,480.00 | 171,911 | |
| 3/19/2020 | Peter Altman | CEO | Buy | 400 | $2.95 | $1,180.00 | 170,711 | |
| 3/12/2020 | Peter Altman | CEO | Buy | 3,400 | $3.15 | $10,710.00 | 166,811 | |
| 8/2/2019 | Simon H Stertzer | Director | Buy | 166,666 | $6.00 | $999,996.00 | | |
Tailor an Options Trading Strategy to Fit Your Needs
From RJO Futures | Ad
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.
Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
BioCardia Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/13/2022 | Renaissance Technologies LLC | 13,700 | $28K | 0.0% | N/A | 0.081% |  |
| 5/13/2022 | Vanguard Group Inc. | 650,523 | $1.35M | 0.0% | +57.9% | 3.856% | |
| 5/13/2022 | Dimensional Fund Advisors LP | 27,407 | $57K | 0.0% | N/A | 0.162% | |
| 5/4/2022 | Commonwealth Equity Services LLC | 49,978 | $0.10M | 0.0% | +18.1% | 0.296% | |
| 1/31/2022 | Commonwealth Equity Services LLC | 42,307 | $82K | 0.0% | +156.5% | 0.251% | |
| 11/5/2021 | Advisor Group Holdings Inc. | 39,257 | $0.12M | 0.0% | -8.4% | 0.233% | |
| 10/29/2021 | Commonwealth Equity Services LLC | 16,492 | $51K | 0.0% | N/A | 0.098% | |
| 9/17/2021 | Virtu Financial LLC | 33,264 | $0.13M | 0.0% | N/A | 0.197% | |
| 8/25/2021 | Marshall Wace LLP | 21,680 | $86K | 0.0% | -45.7% | 0.129% | |
| 8/16/2021 | Marshall Wace LLP | 21,680 | $86K | 0.0% | -45.7% | 0.129% | |
| 8/13/2021 | Renaissance Technologies LLC | 102,230 | $0.41M | 0.0% | -66.5% | 0.609% | |
| 8/13/2021 | Geode Capital Management LLC | 76,825 | $0.30M | 0.0% | +23.6% | 0.457% | |
| 8/13/2021 | Vanguard Group Inc. | 411,969 | $1.64M | 0.0% | +67.8% | 2.453% | |
| 8/10/2021 | CM Management LLC | 329,000 | $1.31M | 0.9% | +5.1% | 1.959% | |
| 8/6/2021 | Magnus Financial Group LLC | 15,000 | $60K | 0.0% | N/A | 0.089% | |
| 5/19/2021 | Squarepoint Ops LLC | 46,945 | $0.20M | 0.0% | N/A | 0.280% | |
| 5/13/2021 | Renaissance Technologies LLC | 305,200 | $1.33M | 0.0% | N/A | 1.817% | |
| 5/12/2021 | Geode Capital Management LLC | 62,168 | $0.27M | 0.0% | +175.6% | 0.370% | |
| 5/12/2021 | CM Management LLC | 313,100 | $1.36M | 1.0% | +36.1% | 1.864% | |
| 2/9/2021 | Bank of New York Mellon Corp | 16,294 | $56K | 0.0% | N/A | 0.131% | |
| 2/5/2021 | CM Management LLC | 230,000 | $0.80M | 0.7% | N/A | 1.851% | |
| 8/17/2020 | Jane Street Group LLC | 14,688 | $35K | 0.0% | N/A | 0.214% | |
| 8/14/2020 | Captrust Financial Advisors | 659,179 | $1.62M | 0.0% | N/A | 9.626% | |
| 8/14/2020 | Advisor Group Holdings Inc. | 85,002 | $0.20M | 0.0% | -7.7% | 1.241% | |
| 5/18/2020 | Advisor Group Holdings Inc. | 92,083 | $0.31M | 0.0% | N/A | 1.349% | |
| 11/27/2019 | Millennium Management LLC | 41,978 | $0.14M | 0.0% | N/A | 0.615% | |
Data available starting January 2016
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Read More on BioCardia
Volume
47 shs
Average Volume
1,050,720 shs
Market Capitalization
$25.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.4
Who are the company insiders with the largest holdings of BioCardia?
